Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS9531 in obstructive sleep apnea and obesity
NCT06974851Phase 3Recruiting
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HRS9531 in obstructive sleep apnea (OSA), obesity, sponsored by Fujian Shengdi Pharmaceuticals. Started Jul 2025; status: recruiting.
02
Drugs
HRS9531
03
Conditions
obstructive sleep apnea (OSA)obesity
Beyond the preview
Go deeper on NCT06974851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06974851.